117 related articles for article (PubMed ID: 18082705)
21. The MYCN enigma: significance of MYCN expression in neuroblastoma.
Tang XX; Zhao H; Kung B; Kim DY; Hicks SL; Cohn SL; Cheung NK; Seeger RC; Evans AE; Ikegaki N
Cancer Res; 2006 Mar; 66(5):2826-33. PubMed ID: 16510605
[TBL] [Abstract][Full Text] [Related]
22. Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma.
Nozato M; Kaneko S; Nakagawara A; Komuro H
Int J Oncol; 2013 Jan; 42(1):134-40. PubMed ID: 23135478
[TBL] [Abstract][Full Text] [Related]
23. Significance of survivin mRNA expression in prognosis of neuroblastoma.
Ito R; Asami S; Motohashi S; Ootsuka S; Yamaguchi Y; Chin M; Shichino H; Yoshida Y; Nemoto N; Mugishima H; Suzuki T
Biol Pharm Bull; 2005 Apr; 28(4):565-8. PubMed ID: 15802787
[TBL] [Abstract][Full Text] [Related]
24. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
25. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
26. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.
Weber A; Imisch P; Bergmann E; Christiansen H
J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335
[TBL] [Abstract][Full Text] [Related]
27. High expression of the novel endothelin-converting enzyme genes, Nbla03145/ECEL1alpha and beta, is associated with favorable prognosis in human neuroblastomas.
Kawamoto T; Ohira M; Hamano S; Hori T; Nakagawara A
Int J Oncol; 2003 Apr; 22(4):815-22. PubMed ID: 12632073
[TBL] [Abstract][Full Text] [Related]
28. Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma.
Shimada A; Hirato J; Kuroiwa M; Kikuchi A; Hanada R; Wakai K; Hayashi Y
Pediatr Blood Cancer; 2008 Feb; 50(2):213-7. PubMed ID: 17941064
[TBL] [Abstract][Full Text] [Related]
29. [Pathology of peripheral neuroblastic tumors].
Wang L; He LJ; Shimada H
Zhonghua Bing Li Xue Za Zhi; 2012 Apr; 41(4):283-8. PubMed ID: 22800533
[No Abstract] [Full Text] [Related]
30. Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas.
Tang XX; Evans AE; Zhao H; Cnaan A; Brodeur GM; Ikegaki N
Med Pediatr Oncol; 2001 Jan; 36(1):80-2. PubMed ID: 11464911
[TBL] [Abstract][Full Text] [Related]
31. Prognostic discrimination among neuroblastomas according to Ha-ras/trk A gene expression: a comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening.
Tanaka T; Sugimoto T; Sawada T
Cancer; 1998 Oct; 83(8):1626-33. PubMed ID: 9781958
[TBL] [Abstract][Full Text] [Related]
32. Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings.
Decock A; Ongenaert M; Vandesompele J; Speleman F
Epigenetics; 2011 Aug; 6(8):962-70. PubMed ID: 21725203
[TBL] [Abstract][Full Text] [Related]
33. Minimal residual disease in peripheral blood stem cell harvests from high-risk neuroblastoma patients.
Avigad S; Feinberg-Gorenshtein G; Luria D; Jeison M; Stein J; Grunshpan A; Sverdlov Y; Ash S; Yaniv I
J Pediatr Hematol Oncol; 2009 Jan; 31(1):22-6. PubMed ID: 19125082
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical expressions of Cap43 and Mina53 proteins in neuroblastoma.
Fukahori S; Yano H; Tsuneoka M; Tanaka Y; Yagi M; Kuwano M; Tajiri T; Taguchi T; Tsuneyoshi M; Kojiro M
J Pediatr Surg; 2007 Nov; 42(11):1831-40. PubMed ID: 18022432
[TBL] [Abstract][Full Text] [Related]
35. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma.
Alaminos M; Mora J; Cheung NK; Smith A; Qin J; Chen L; Gerald WL
Cancer Res; 2003 Aug; 63(15):4538-46. PubMed ID: 12907629
[TBL] [Abstract][Full Text] [Related]
36. Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction.
Sestini R; Orlando C; Peri A; Tricarico C; Pazzagli M; Serio M; Pagani A; Bussolati G; Granchi S; Maggi M
Clin Cancer Res; 1996 Oct; 2(10):1757-65. PubMed ID: 9816127
[TBL] [Abstract][Full Text] [Related]
37. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
[TBL] [Abstract][Full Text] [Related]
38. Expression of TSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation.
Ando K; Ohira M; Ozaki T; Nakagawa A; Akazawa K; Suenaga Y; Nakamura Y; Koda T; Kamijo T; Murakami Y; Nakagawara A
Int J Cancer; 2008 Nov; 123(9):2087-94. PubMed ID: 18726896
[TBL] [Abstract][Full Text] [Related]
39. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.
Asgharzadeh S; Pique-Regi R; Sposto R; Wang H; Yang Y; Shimada H; Matthay K; Buckley J; Ortega A; Seeger RC
J Natl Cancer Inst; 2006 Sep; 98(17):1193-203. PubMed ID: 16954472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]